Notice2026-19000
Notice Pursuant to the National Cooperative Research and Production Act of 1993-The Customer Experience Hub
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 16, 2026
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 91 Issue 178 (Wednesday, September 16, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 178 (Wednesday, September 16, 2026)]
[Notices]
[Page 58711]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-19000]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--The Customer Experience Hub
Notice is hereby given that, on January 7, 2026, pursuant to
section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), The Customer Experience Hub
(``CX Hub'') has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing changes in
its membership. The notifications were filed for the purpose of
extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Advanced Biomimetic Sensors, Inc., Bethesda, MD; Advanced
RNA Vaccine Technologies, Inc., North Bethesda, MD; Albert Einstein
College of Medicine, Bronx, NY; Auspex Medix LLC, Williamsville, NY;
Beacon Biosignals, Inc., Boston, MA; Beth Israel Deaconess Hospital--
Needham, Inc., Needham, MA; Bethany R. Russell, Ph.D. P.A, Babcock
Ranch, FL; Binary Pharmaceuticals LLC, Hot Springs, AR; Bridgesource
Medical, Corp., Austin, TX; Broad Clinical Laboratories LLC, Cambridge,
MA; Credence Management Solutions Limited Liability Company, Mclean,
VA; Delix Therapeutics, Inc., Palo Alto, CA; Droneup LLC, Virginia
Beach, VA; Earlham Institute, Norwich, UNITED KINGDOM OF GREAT BRITAIN
AND NORTHERN IRELAND; Enveda Therapeutics, Inc., Boulder, CO; Epitel,
Inc., Salt Lake City, UT; Georgia Tech Applied Research Corp., Atlanta,
GA; Healthspan Action Coalition, Wellington, FL; Hi LLC, Culver City,
CA; Huru Ltd, London, UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN
IRELAND; Inner Cosmos, Inc., Scotts Valley, CA; Invi Mindhealth, Inc.,
Parker, CO; IsoLinQ, Sugar Land, TX; Ist, LLC, Birmingham, AL; KBO
Systems, Inc., Aurora, CO; Kintsugi Mindful Wellness, Inc., Berkeley,
CA; Monash University Clinical Psychedelic Lab, Notting Hill,
COMMONWEALTH OF AUSTRALIA; Motif Neurotech, Inc., Houston, TX; Neuro
Animation, Inc., Columbia Fls, MT; Neuroblox, Inc., Cambridge, MA;
NeuroSigma, Inc., Los Angeles, CA; North Carolina State University
Foundation, Inc., Raleigh, NC; Novelna, Inc., Santa Clara, CA; NRx
Pharmaceuticals, Wilmington, DE; Osmind, Inc., San Francisco, CA; Oui
Therapeutics, Inc., New Haven, CT; Pax Neuroscience, Inc., Glenview,
IL; PointHealth AI, San Francisco, CA; Psylo, Inc., Boulder, CO;
Relevant LLC; Issaquah, WA; Sage Research Consulting LLC, Mason, OH;
Salura Health LLC, McLean, VA; Scottsdale Research Institute, Phoenix,
AZ; Senseye, Inc., Austin, TX; Soar Technology LLC, Ann Arbor, MI;
Sunstone Therapies, Inc., Rockville, MD; Tactical Mind Research
Coalition, St. Petersburg, FL; The Methuselah Foundation, Springfield,
VA; The Regents of the University of Colorado, Boulder, CO; The Stories
and Wisdom Company, Issaquah; WA; The Virtual Reality Medical Center, a
Professional Medical Corporation, San Diego, CA; Toxpath Solutions LLC,
Vancouver, WA; University of Arizona, Tucson, AZ; University of
California Santa Cruz, Santa Cruz, CA; University of California, Davis,
Davis, CA; University of Florida, Gainesville, FL; University of North
Carolina at Chapel Hill, Chapel Hill, NC; USAPI Pharma PBC, St.
Augustine, FL; Vaccinity, Dallas, TX; and Yale Stress Center, New
Haven, CT have been added as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and CX Hub intends to file additional
written notifications disclosing all changes in membership.
On January 11, 2024, CX Hub filed its original notification
pursuant to section 6(a) of the Act. The Department of Justice
published a notice in the Federal Register pursuant to section 6(b) of
the Act on April 16, 2024 (89 FR 26929).
The last notification was filed with the Department on October 2,
2025. A notice was published in the Federal Register pursuant to
section 6(b) of the Act on February 23, 2026 (91 FR 8525).
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2026-19000 Filed 9-15-26; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on September 16, 2026.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.